Biden's Marijuana Rescheduling Faces Scrutiny Over Limited Practical Impact
The move to reclassify cannabis to Schedule III promises regulatory shifts but falls short of broader legalization goals.
Overview
- Rescheduling marijuana to Schedule III reduces regulatory barriers for medical research and tax deductions for businesses.
- The change does not decriminalize marijuana use or legalize state-licensed cannabis businesses under federal law.
- Critics argue the rescheduling fails to address the injustices of the War on Drugs or harmonize federal and state cannabis policies.
- New federal regulations will dictate how cannabis can be prescribed and dispensed, requiring FDA approval for medical use.
- Financial institutions remain hesitant to serve cannabis businesses due to persistent legal risks under federal law.